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Abstract
Background: Recent achievement in genetics and epigenetics has led to the exploration of the pathogenesis of
systemic lupus erythematosus (SLE). Identification of differentially expressed genes and their regulatory mechanism(s)
at whole-genome level will provide a comprehensive understanding of the development of SLE and its devastating
complications, lupus nephritis (LN).
Methods: We performed whole-genome transcription and DNA methylation analysis in PBMC of 30 SLE patients,
including 15 with LN (SLE LN+) and 15 without LN (SLE LN−), and 25 normal controls (NC) using HumanHT-12
Beadchips and Illumina Human Methy450 chips. The serum proinflammatory cytokines were quantified using Bio-plex
Human Cytokine 27-plex assay. Differentially expressed genes and differentially methylated CpG were analyzed with
GenomeStudio, R, and SAM software. The association between DNA methylation and gene expression were tested.
Gene interaction pathways of the differentially expressed genes were analyzed by IPA software.
Results: We identified 552 upregulated genes and 550 downregulated genes in PBMC of SLE. Integration of DNA
methylation and gene expression profiling showed that 334 upregulated genes were hypomethylated, and 479
downregulated genes were hypermethylated. Pathway analysis on the differential genes in SLE revealed significant
enrichment in interferon (IFN) signaling and toll-like receptor (TLR) signaling pathways. Nine IFN- and seven TLR-related
genes were identified and displayed step-wise increase in SLE LN− and SLE LN+. Hypomethylated CpG sites were
detected on these genes. The gene expressions for MX1, GPR84, and E2F2 were increased in SLE LN+ as compared to
SLE LN− patients. The serum levels of inflammatory cytokines, including IL17A, IP-10, bFGF, TNF-α, IL-6, IL-15, GM-CSF,
IL-1RA, IL-5, and IL-12p70, were significantly elevated in SLE compared with NC. The levels of IL-15 and IL1RA correlated
with their mRNA expression. The upregulation of IL-15 may be regulated by hypomethylated CpG sites in the promotor
region of the gene.
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Conclusions: Our study has demonstrated that significant number of differential genes in SLE were involved in IFN, TLR
signaling pathways, and inflammatory cytokines. The enrichment of differential genes has been associated with aberrant
DNA methylation, which may be relevant to the pathogenesis of SLE. Our observations have laid the groundwork for
further diagnostic and mechanistic studies of SLE and LN.
Keywords: Systemic lupus erythematous, Whole-genome transcription, DNA methylation, Multiplex cytokine assay,
Peripheral blood mononuclear cells, Lupus nephritis
Background
Systemic lupus erythematosus (SLE) is a potentially severe
autoimmune disease characterized by intermittent epi-
sodes of increased disease activity that require treatment
with immunosuppressive agents [1]. Renal involvement
affects more than 60 % of patients with SLE, and is a
major contributor to morbidity and mortality [2]. Neph-
ritis remains one of the most devastating complications of
lupus, and is an important cause of chronic renal failure
despite the availability of new therapeutic regimens [3].
Optimizing the management of lupus nephritis (LN) is
therefore important, both to reduce the healthcare burden
to society and to improve the outcome of patients [4]. SLE
should be closely monitored for renal manifestations, early
diagnosis and treatment are essential for renal preserva-
tion [5]. The most commonly used marker of renal disease
is urinary protein. Spot urinary protein-to-creatinine ratio
is currently recommended as a marker. However, it is not
sufficiently sensitive to detect early nephritis. Conven-
tional markers of active renal disease are serum levels
of anti-dsDNA, anti-C1q antibody, and complement
levels. However, the sensitivity of these markers varied
greatly depending on the assay system used. The speci-
ficity ranges between 50 and 75 % for active renal dis-
ease [6, 7]. A better understanding of the pathogenesis
of LN is an important step in identifying more bio-
markers and targeted therapeutic approaches [8].
Substantial research has helped define the pathogenic
mechanisms of SLE renal manifestations [9]. A number of
genetic polymorphisms have been associated with lupus, it
is now recognized that multiple genes, each making only a
small contribution, account for the risk of developing SLE.
Several genome-wide scans have allowed major advances
in the identification of genetic regions predisposing to
SLE, bringing the total number of validated loci to more
than 50 [10]. However, many nongenetic factors (such as
environment) have now been linked to lupus, environ-
mentally induced epigenetics may also play a critical role
in autoimmune immunopathology [11]. Global epigenetic
modification, such as DNA methylation and chromatin
modification, are directly influenced by the environment,
and play an important role in the pathogenesis of SLE [12].
Epigenetic alterations have an important effect on gene
expression regulation. Many studies have investigated the
association between genetics, DNA methylation, and gene
expression in SLE [13–16]. In previous work, hypomethyla-
tion of global genomic DNA has been demonstrated in
several autoimmune-related gene promoters in isolated T
cells from SLE. Genes with aberrant DNA demethylation
identified in lupus T cells include ITGAL, CD70, PRF1, and
the X chromosome gene CD40LG [17–21]. Similar data
are not yet available for LN, and most of the association
studies to date have yielded inconsistent results across
populations [22].
In the present study, we analyzed the DNA methylation
distribution and the relevant mRNA expression variation
in peripheral blood mononuclear cells (PBMC) from SLE
patients with or without LN using whole-genome DNA
methylation and gene expression arrays. We also profiled
the levels of inflammatory cytokines in sera of SLE pa-
tients by bead-based multiplex assays. The integration of
genome-wide gene transcription and DNA methylation
expended our insight into the mechanisms affecting epi-
genetic alteration, gene expression, and LN susceptibility.
Combined with the cytokine expression, our data provide
a unique resource for identifying biomarkers that may be
useful in the diagnosis of lupus nephritis.
Methods
SLE patients and controls
We studied 30 SLE patients (15 SLE with lupus nephritis
(LN+) and 15 SLE without lupus nephritis (LN−)) and 25
normal controls (NC). Patients and controls were matched
for age, sex, and ethnicity. All SLE patients meet the
American College of Rheumatology (ACR) classification
criteria for SLE [23]. The clinical features of SLE pa-
tients included in this study are shown in Table 1. SLE
LN+ is defined as clinical and laboratory manifestations
that meet ACR criteria (persistent proteinuria >0.5 g/day or
greater than 3+ by dipstick, and/or urine cellular casts
including red blood cells (RBC), hemoglobin, granular,
tubular, or mixed) [2, 23]. A review of the ACR criteria has
recommended that “active urinary sediment” (>5 RBCs/
high-power field (HPF), >5 white blood cells (WBC)/HPF
in the absence of infection) can be substituted for cellular
casts [24]. The patients enrolled in the study did not have
lymphopenia or cytopenia in previous history. This study
was approved by the institutional review board at Xiangya
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Hospital, Central South University of China (Changsha,
Hunan, China). All the participants in the study signed a
written informed consent prior to participation [2].
DNA and RNA isolation
Peripheral blood samples were obtained from SLE patients
and normal controls. The PBMC were isolated from hepa-
rinized blood by density gradient centrifugation over Ficoll-
Paque Plus (GE Healthcare, Piscataway, NJ, USA). Total
RNA was isolated from PBMC by standard phenol–
chloroform extraction using Trizol reagent (Invitrogen
Life Technologies, Carlsbad, CA, USA) according to the
manufacturer’s instructions and the concentration was
measured on Nanodrop ND-1000 Spectrophotometers
(Thermo Fisher Scientific, Waltham, MA, USA). RNA
quality was checked on Bioanalyzer Nanochip (Agilent
Technologies, Santa Clara, CA, USA) and the samples
with RNA integrity number (RIN) >7 were required for
microarray analysis. Genomic DNA was isolated from
whole blood cells using genomic DNA extraction kits
(Life Technologies, Gaithersburg, MD, USA) and DNA
integrity was analyzed by agarose gel electrophoresis.
Genome-wide DNA methylation analysis
DNA methylation status of 485,000 CpG sites across the
whole genome was analyzed using the Illumina Human-
Methylation 450 BeadChip array. The array covers 99 % of
RefSeq genes, with an average of 17 CpG sites per gene
region distributed across the promoter, 5′UTR, first exon,
gene body, and 3′UTR. It covers 96 % of CpG islands,
with additional coverage in island shores and the regions
flanking them (Illumina, Inc., San Diego, CA, USA).
Genomic DNA (1 μg) extracted from PBMC was bisul-
fite converted using EZ DNA Methylation kit (Zymo
Research Corp, Orange, CA, USA. cat. no. D5004), and
utilizing a cyclic denaturation step during the conversion
reaction. Four microliters of bisulfite-converted DNA were
used for hybridization on Infinium HumanMethylation 450








SLE LN− vs. NC SLE LN+ vs. NC SLE LN+ vs. SLE LN−
Age (mean + SD) 32.2 ± 9.04 28.2 ± 6.7 30.13 ± 7.68 n.s. n.s. n.s.
Sex (M/F) 5/20 2/13 2/13 n.s. n.s. n.s.
Disease duration (months) - 4.90 ± 4.18 3.33 ± 4.21 - - n.s.
SLEDAI - 9.06 ± 4.06 14.93 ± 4.65 - - 0.001
1997 ACR classification criteria for SLE
Malar rash - 8 11 - - -
Discoid rash - 1 3 - - -
Photosensitivity - 4 3 - - -
Oral ulcers - 2 1 - - -
Nonerosive arthritis - 8 6 - - -
Pleuritis or pericarditis - 1 3 - - -
Renal disorder - 0 15 - - -
Neurological disorder - 1 0 - - -
Hematological disorder - 2 7 - - -
Immunological disorder - 11 12 - - -
Positive antinuclear antibody (ANA) - 15 14 - - -
WBC (×109/L)a - 6.64 ± 0.70 6.45 ± 0.90 - 0.866
Neutrophils (×109/L)b - 5.00 ± 0.69 4.74 ± 0.76 - 0.799
Lymphocytes (×109/L)c - 1.54 ± 0.21 1.22 ± 0.18 - 0.246
C3 (mg/dL) - 534.5 ± 280.1 293.2 ± 196.2 - 0.0108
C4 (mg/dL) - 133.2 ± 147.4 88.02 ± 86.48 - 0.3145
There were no significant difference in age and gender between normal controls and SLE. SLE LN+ patients exhibited higher disease activity (SLEDAI score) and
lower level of complement C3 than SLE LN-. Complete blood count (CBC) in SLE patients showed that the count of white blood cells (WBC), neutrophils, and
lymphocytes are within the normal range in SLE patients
SLE systemic lupus erythematosus, NC normal controls, SLE LN+ SLE with lupus nephritis, SLE LN− SLE without lupus nephritis, SLEDAI SLE Disease Activity Index,
n.s. not significant, ACR American College of Rheumatology, C3 complement component 3, C4 complement component 4
aNormal range of white blood cell (WBC) count: 3.5–10.5 × 109/L
bNormal range of neutrophils: 2.0–7.0 × 109/L
cNormal range of lymphocytes: 1.0–3.0 × 109/L
dt test, p < 0.05 means significant
Zhu et al. Arthritis Research & Therapy  (2016) 18:162 Page 3 of 17
BeadChip kit. According to the Illumina Infinium HD
Methylation protocol, the following steps were performed,
whole-genome amplification, end-point fragmentation, pre-
cipitation, and resuspension. The resuspended samples
were hybridized onto HumanMethylation 450 BeadChips
at 48 °C for 18 hours. Then unhybridized and nonspe-
cifically hybridized DNA were washed away, followed
by a single nucleotide extension and repeated rounds of
staining. Finally, the BeadChip was washed, coated, and
scanned. After scanning, the intensities of images were
extracted using GenomeStudio Methylation module
software (Illumina, Inc.). The methylation score for each
CpG was represented as a β value according to the fluores-
cent intensity ratio. A β value may take any value between
0 (nonmethylated) and 1 (completely methylated). Expres-
sion values were extracted, filtered, and normalized using
an R package (RnBeads) [25]. The normalized methylation
data were analyzed by significance analysis of microarrays
(SAM, Stanford University) [26]. The significant differen-
tially methylated sites with FDR <0.05, fold change >1.2
were selected.
Gene expression studies
Illumina HumanHT-12 v4.0 Expression Beadchips
(Illumina, Inc.) were used for mRNA transcription profil-
ing. The platform contains 47,323 transcripts. Each RNA
sample was amplified using the Illumina TotalPrep RNA
Amplification kit (Thermal Fisher Scientific) with biotin-
UTP (Enzo Life Sciences, Inc., Farmingdale, NY, USA)
labeling. The TotalPrep Illumina RNA Amplification kit
uses T7-oligo(dT) primer to generate single-stranded
cDNA followed by a second-strand synthesis to generate
double-stranded cDNA, purifies through spin column, uses
T7 RNA polymerase to synthesize biotin-labeled cRNA,
and purifies again. The cRNA was then quantified using
the ND-1000 Spectrophotometer (Thermo Fisher Scien-
tific). A total of 1.5 μg cRNA from each sample was hybrid-
ized on each array using standard Illumina protocols with
streptavidin-Cy3 (Amersham Biosciences Corp., Piscataway,
NJ, USA) being used for detection. Slides were scanned on
an Illumina HiScan scanner and analyzed using GenomeS-
tudio (Illumina, Inc.). The raw files of Illumina HumanHT-
12 v4.0 Expression array were extracted and normalized
(Quantile) in GenomeStudio Module. Normalized raw data
were filtered by detection p value and median centered by
using the Genespring software (Silicon Genetics, Redwood
City, CA, USA). Expression data was performed by t test
without any error correction on the samples. Genes were
considered statistically significant at p < 0.05.
Multiplex cytokine assays
Diluted plasma specimens were prepared for analysis in
a 96-well plate utilizing the Bio-plex Human Cytokine
27-plex assay (Bio-Rad Laboratories, Veenendaal, The
Netherlands) according to the manufacturer’s instruc-
tions. The 27-plex assay kit contains beads conjugated
with monoclonal antibodies specific for interleukin (IL)-
17A, regulated on activation, normal T cell expressed and
secreted (RANTES), platelet-derived growth factor-BB
(PDGF-BB), IL-2, IL-4, IL-13, basic fibroblast growth factor
(bFGF), macrophage inflammatory protein 1 alpha (MIP-
1α), IFN-gamma-inducible protein 10 (IP-10), monocyte
chemoattractant protein 1 (MCP-1), granulocyte colony-
stimulating factor (G-CSF), Eotaxin, tumor necrosis factor
alpha (TNF-α), IL-6, IL-9, IL-15, granulocyte-macrophage
colony-stimulating factor (GM-CSF), IL-1RA, IL-5, IL-
12p70, interferon (IFN)-ϒ, IL-1β, IL-7, IL-8, MIP-1β and
vascular endothelial growth factor (VEGF). Analyses were
quantified using a Magpix analytical test instrument, which
utilizes xMAP technology (Luminex Corp., Austin, TX,
USA) and xPONENT 4.2 software (Luminex Corp.). Con-
centrations of cytokines (pg/ml) were determined on the
basis of the fit of a standard curve for mean fluorescence
intensity versus pg/ml.
Real-time PCR validation of the differential gene
expression
Differentially expressed genes were validated using
Taqman assays on a 7900HT Fast Real-Time PCR sys-
tem (Applied Biosystems, Foster City, CA, USA). The
assay was performed by using a TaqMan RNA-to-CT
1-Step kit (Applied Biosystems) in a total volume of 20 μl,
which contained a final concentration of 900 nM sense
and antisense primers, 250 nM Taqman gene probe, 1 ×
TaqMan RT Enzyme Mix, and 1 × TaqMan RT-PCR Mix.
The cDNA amplification were monitored using 7900HT
Fast Real-Time PCR system under the conditions of 48 °C
for 15 min, 95 °C for 10 min, and 40 cycles of 95 °C for 15
s and 60 °C for 1 min. This assay was carried out in tripli-
cate for each sample, including a no-template control.
The relative quantity (RQ) of the gene expression in each
sample was calculated by normalizing to housekeeping
gene GAPDH.
Pathway analysis
The Ingenuity Pathway Analysis (IPA) tool was used
to identify gene networks, functions, and canonical
pathways. The IPA software was used for its ability to
analyze mRNA data in the context of known biological
response and regulatory networks. The score for each net-
work was derived from a p value that indicates the ex-
pected likelihood of the focus genes being present in a
network compared with that expected by chance. The
software determines the probability that each biological
function assigned to that data set was due to chance alone
(http://www.ingenuity.com/).
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Statistical analysis
Data are shown as mean values and standard errors of the
means. The univariate comparisons were done using a
one-way ANOVA or two-sample t test, and multivariable
adjustments were done using ANCOVAR to simultan-
eously adjust for age, SLE Disease Activity Index (SLEDAI)
score, and the health status satisfaction score. All p values
were from two-sided tests. Correlations between pairs of
continuous variables were done using Pearson’s R. Dichot-
omized variables were compared using Fisher’s exact chi-
square test. Bonferroni correction was applied in some of
the analyses. p values of < 0.05 were considered significant.
All analyses were performed using SAS version 9.3 soft-
ware (SAS Institute Inc., Cary, NC, USA). Graphics were
carried out using Prism version 6.0 (GraphPad, San Diego,
CA, USA).
Results
Aberrant mRNA transcription in SLE
First, we investigated the gene expression profiles in PBMC
of 30 SLE patients (SLE), including 15 SLE with LN (SLE
LN+) and 15 SLE without LN (SLE LN−), and 25 matched
normal controls (NC) using Illumina Human HT-12 v4.0
Beadchips. By comparing the gene transcription levels be-
tween SLE (including SLE LN+ and SLE LN−) and NC, we
identified 879 upregulated and 855 downregulated genes
which are significant (p < 0.05) in SLE as compared with
NC (Fig. 1a). Further analysis was performed to compare
a
b
Fig. 1 Differentially expressed genes in the PBMC of SLE patients compared with normal controls. a Venn diagram shows the number of upregulated
genes (left panel) and downregulated genes (right panel) in three comparisons: SLE vs. NC, SLE LN− vs. NC, and SLE LN+ vs. NC. There are 552 upregulated
and 550 downregulated genes in common in all three comparisons. b Heat map shows hierarchical clustering of the commonly up- and downregulated
genes in the three comparisons. NC normal controls, SLE systemic lupus erythematosus, SLE LN+ SLE with lupus nephritis, SLE LN− SLE without
lupus nephritis
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the gene expression differences between SLE LN+ vs. NC
and SLE LN− vs. NC. There are 1000 upregulated and 1028
downregulated in SLE LN+ vs. NC, and 834 upregulated
and 806 downregulated genes in SLE LN− vs. NC (Fig. 1a).
By Venn diagram analysis, we were able to identify 552
upregulated genes and 550 downregulated genes which are
common in all three comparisons (Fig. 1a, Additional file 1:
Table S1, and Additional file 2: Table S2), indicating that
these common genes are consistently differentially reg-
ulated in SLE as compared to the NC group. The pro-
file of the differentially expressed genes in all samples
was shown as a heat map in Fig. 1b. The gene expres-
sion microarray data has been submitted to the GEO
database with accession number GSE81622. The list of
the differentially expression genes in each comparison
was shown in Additional file 1: Table S1 and Additional
file 2: Table S2.
Aberrant DNA methylation in SLE
Next, we performed a global DNA methylation analysis on
the same sets of SLE patients and normal controls using a
gene chip containing 485,000 CpG sites across the whole
genome. Figure 2 showed the numbers of differentially
methylated CpG sites in three comparisons: SLE vs. NC,
SLE LN+ vs. NC, and SLE LN− vs. NC (Fig. 2a). There are
1813 hypermethylated sites and 3785 hypomethylated sites
which are common in all three comparisons (Fig. 2a,
Additional file 3: Table S3 and Additional file 4: Table S4).
The distribution and location of the hypo- and hyper-
methylated sites are shown is Fig. 2b. Nearly half of the
differentially methylated sites (42.95 % of the hypomethy-
lated and 42.99 % for hypermethylated sites) are located
on or in the vicinity of the promoter regions, including
TSS200 and TSS1500, which is highly suggestive of methy-
lation as a regulatory mechanism on gene transcription. A
high percentage of altered methylation sites are also clus-
tered within the gene body, 5′UTR, and first exon (Fig. 2b).
The list of the differentially methylated CpG sites in each
comparison was shown in Additional file 3: Table S3 and
Additional file 4: Table S4. The DNA methylation for all
samples has been submitted to the GEO database with
accession number GSE81622.
Correlation of gene expression and DNA methylation in SLE
In order to determine the potential effects of the aberrant
DNA methylation on the abnormal gene expression in
SLE, we investigated the methylation status of the 552
commonly upregulated genes and 550 commonly down-
regulated genes in SLE. Among the 552 upregulated genes,
333 genes (60.5 %) have one or more hypomethylated
CpG sites (total 1065 CpG site in 333 genes as shown
in Fig. 2c, left panel; and Additional file 5: Table S5);
while among the 550 downregulated genes, hyper-
methylated CpG sites were found in 479 genes (87.1 %)
(Fig. 2c, right panel; and Additional file 5: Table S5).
Our data suggested that DNA methylation may play an
important role in the regulation of gene expression in
the development of SLE.
Functional analysis on the genes differentially
expressed in SLE
To decipher the molecular pathways associated with dys-
regulated genes in SLE, we performed Ingenuity Pathway
Analysis (IPA) on the differentially expressed genes which
are common in all three comparisons. The molecular path-
ways most significantly correlated with the 552 upregu-
lated genes are showed in Fig. 3a. The top five pathways
enriched in the upregulated genes including interferon
signaling (1.48E-07), role of pattern recognition recep-
tors in recognition of bacteria and viruses (1.09E-06),
altered T cell and B cell signaling in rheumatology
arthritis (9.43E-05), cell cycle: G2/M DNA damage check-
point regulation (2.56E-04) and toll-like receptor signaling
(6.58E-04) (Fig. 3a). Figure 3b exhibited the molecular
pathways related with the 550 downregulated genes,
including natural killer cell signaling (2.84E-19), T cell re-
ceptor signaling (3.89E-10), iCOS-iCOSL signaling in T
helper cells (2.19E-09), cytotoxic T lymphocyte-mediated
apoptosis of target cells (7.38E-08) and role of NFAT in
regulation of the immune response (8.89E-08) (Fig. 3b).
DNA hypomethylation related with the overexpression
of IFN-related genes in SLE
Among the molecular pathways modulated by aberrantly
expressed genes in SLE, type I IFN (IFN-I) signaling path-
way showed highest association with the upregulated genes
in SLE. The IFN-related genes which are highly expressed
in SLE were significantly enriched in this pathway (Fig. 4a).
Nine of the IFN-I-related genes, including IFI35, IFIT1,
IFIT3, IFITM2, IFITM3, IFNGR2, myxovirus (influenza)
resistance 1 (MX1), OAS1 and STAT1, showed a stepwise
increase from NC to SLE LN− to SLE LN+, although the
difference between SLE LN− and SLE LN+ on these genes
(except MX1) was not statistically significant (Fig. 4b), sug-
gesting that the dysregulation of IFN pathway genes may
play an important role in the pathogenesis of SLE. The
gene expression data on some IFN genes were further con-
firmed by real-time PCR and data was shown in Additional
file 6: Figure S1. Based on the average expression of these
nine IFN genes, we calculated an IFN score for each sam-
ple. The mean IFN score for SLE patients (15.23 ± 5.95)
was significantly greater than NC (9.00 ± 2.94) (p < 0.0001).
The IFN score for SLE LN+ (22.57 ± 12.84) was slightly
higher than SLE LN− (16.13 ± 8.36) but not statistically
significant (p > 0.1) (Fig. 4c).
In order to understand if the increased expression of
IFN signaling genes in SLE were regulated by altered
DNA methylation, we examined the methylation status
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of the CpG sites on the upregulated IFN genes in all NC
and SLE samples. Among the 47 CpG sites in the nine
IFN-related genes, 41 CpG sites exhibited decreased methy-
lation (hypomethylation) in SLE patients compared with
NC on mean β value (p < 0.05), including two sites on four
genes (IFI35, IFITM2, IFIT1 and OAS1), three on IFIT3,
five on IFITM3, six sites on STAT1, eight sites on IFNGR2
and 11 sites on MX1 (Fig. 4d). Shown in Fig. 4e are the six
CpG sites which exhibited the greatest methylation change
on the IFN genes between SLE and NC, four on MX1
(cg22862203, cg26312951, cg16785077, cg21549285), one
on IFIT3 (cg06188083) and one on IFIT1 (cg05552874)
Fig. 2 Differentially methylated CpG sites in PBMC of SLE patients compared with normal controls by DNA methylation analysis. a Venn diagram
showing the number of hypomethylated (left panel) and hypermethylated CpG sites (right panel) in three comparisons, SLE vs. NC, SLE LN+ vs. NC,
and SLE LN− vs. NC. A total of 1813 hypomethylated CpG sites and 3785 hypermethylated CpG sites are in common in all three comparisons.
b The distribution of differentially methylated CpG sites on the genome. The bar charts showed the genomic distribution of hypomethylated
(left panel) and hypermethylated (right panel) probes across different genomic regions: TSS1500 and TSS200 (probes located within 1500 and 200
bp from transcription start site, respectively); 5′UTR region; first exon; gene body and 3′UTR region. c Heat maps depicting cluster of the 1065
hypomethylation sites in 333 of 552 upregulated genes, which have one or more hypomethylated CpG sites, and 3024 hypermethylation sites in
487 of 550 downregulated genes, which have one or more hypermethylated sites. NC normal controls, SLE systemic lupus erythematosus, SLE LN+ SLE
with lupus nephritis, SLE LN− SLE without lupus nephritis
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(Fig. 4e). The methylation of these sites reversely corre-
lated with the transcription levels of the corresponding
genes in PBMC (Fig. 4e, f ).
DNA hypomethylation associated with higher
transcription of the genes in the toll-like receptor
signaling pathway in SLE
In addition to interferon signaling pathway, we noted
that the expression of several genes related to the toll-
like receptor signaling (TLR) pathway were also elevated in
SLE. TLRs play an essential role in the innate immune sys-
tem and regulate a pro-/anti-inflammatory balance (Fig. 5a).
We found that mRNAs for cluster of differentiation 14
(CD14), eukaryotic translation initiation factor 2-alpha kin-
ase 2 (EIF2AK2), IL1RN, interleukin-1 receptor-associated
kinase 3 (IRAK3), TLR1, TLR4, TLR7 and TLR8 were sig-
nificantly upregulated in SLE compared with NC (Fig. 5b).
The expression of the TLR7 and EIF2AK2 genes were
a
b
Fig. 3 Gene interaction networks among the common up- and downregulated genes in the PBMC of SLE using IPA software. a Top ten pathways
showing inter-relationships among 552 upregulated genes in SLE. b Top ten pathways showing inter-relationships among the 550 downregulated
genes in SLE. The top ten pathways are represented by the red bar. The lines connecting the bars depict possible gene interactions in the network.
The expected likelihood of the gene involved in the pathway was indicated by p value in the network






Fig. 4 (See legend on next page.)
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higher in SLE LN+ as compared to SLE LN−, but the
change was not statistically significant (Fig. 5b).
We then examined the DNA methylation status on the
CpG sites of these differentially expressed genes. There
are multiple CpG sites (eight on IRAK3, two on EIF2AK2,
four on TLR4, three on IL-1RA, two on TLR8 and one on
TLR7), which showed different methylation between SLE
and NC. The most significantly hypomethylated sites
were found on EIF2AK2 (cg14126601 and cg17326313)
and IRAK3 (cg19995654, cg12866960, and cg07914866)
(Fig. 5c). The analysis showed that the increase in gene
expression was inversely correlated with the reduction
in DNA methylation level (decreased Δβ) on the same
genes, suggesting that DNA hypomethylation may be
involved in regulation of gene expression for the TLR
pathway in SLE.
Aberrant mRNA expression in SLE with LN
In order to identify the genes which may play a role in the
development of LN, we compared the gene expression
profiles in PBMC between SLE LN+ and SLE LN− pa-
tients. From the 552 common upregulated and 550 com-
mon downregulated genes in SLE, we only identified three
genes (MX1, G protein-coupled receptor 84 (GPR84), E2F
transcription factor 2 (E2F2)), which were significantly
increased in SLE LN+ compared with both NC and SLE
LN− (p < 0.05, Fig. 6). We then checked the methylation
status of the three upregulated genes and no significant
methylation change was identified on these genes between
SLE LN+ and SLE LN− patients.
Aberrant level of serum cytokine/chemokine in SLE and
their transcriptional regulation
Cytokines are immunoregulatory mediators which play
important roles in the pathogenesis of SLE. In an effort to
understand the transcriptional regulation on serum cyto-
kines, we performed quantitative analysis on 27 cytokines/
chemokines in the sera of SLE and NC using a bead-based
multiplex assay. Fifteen of the 27 serum factors, including
IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-15, IL-17A,
bFGF, MCP-1, IP-10, G-CSF, GM-CSF, IL-1RA and TNF-
α were significantly higher in SLE LN− and SLE LN+,
compared with NC (Fig. 7a, Additional file 7: Table S6).
However, two cytokines, PDGF-BB and RANTES, were
significantly lower in the two SLE groups compared with
NC (Fig. 7a). There was no significant difference on the
serum levels of the cytokines between SLE LN+ patients
and their SLE LN− counterparts (Fig. 7a, Additional file 7:
Table S6). At the transcription level, we found that IL-15
mRNA was elevated in SLE, and RANTES (chemokine
(C-C motif) ligand 5 (CCL5)) mRNA was decreased in
SLE, compared with NC (Fig. 7b), indicating that the serum
level of these two cytokines corresponded with their mRNA
expression in PBMC. We further checked the DNA methy-
lation status on IL-15 and CCL5, and identified six of 11
methylation sites (cg01856970, cg02934500, cg25546588,
cg16655388, cg26269613, and cg20060523) on IL-15, which
are located at 5′UTR, TSS1500, and TSS 200 regions, were
hypomethylated in both SLE LN+ and SLE LN− patients in
relation to NC (Fig. 7c). We also found three CpG sites
(cg00447324, cg08656816, and cg19411729) at the 5′UTR
region of CCL5 (RANTES) gene were hypermethylated in
SLE compared with controls (Fig. 7c).
Discussion
Multiple studies on a variety of cell types have demon-
strated altered gene expression and DNA methylation
patterns in autoimmune diseases, providing important
new directions toward understanding the pathogenesis of
immune-mediated diseases [27, 28]. A number of studies
have compared gene expression in PBMC from patients
with SLE versus healthy individuals or other autoimmune
conditions, which provide substantial advantages in the
search for diagnostic and prognostic biomarkers in auto-
immune disease [29, 30]. But LN remains a major chal-
lenge and one of the most severe manifestations of SLE.
Early diagnosis and intervention are essential for favorable
patient outcomes [31]. It would be of great help to identify
biomarkers so that we could assess LN activity or kidney
damage, and predict an imminent exacerbation of renal
disease accurately [2].
In this study, we performed an unbiased genome-wide
gene transcription and DNA methylation study in PBMC
from SLE patients with LN and without LN and compared
(See figure on previous page.)
Fig. 4 Upregulated genes in PBMC of SLE were significantly enriched in the interferon signaling pathway. a A diagram showing the interferon
signaling pathway and upregulated genes involved in the network. b Array-based mRNA expression represented by normalized intensity in SLE
LN+, SLE LN−, and normal controls.*Indicates p < 0.05 as compared to normal controls. c Interferon scores for SLE patients and controls. The IFN
score for each sample was derived from the combined fold change of relative intensity for each gene. The mean intensity in normal controls for
each gene was calculated and used as baseline intensity for the gene. Then the intensity of mRNA expression for each gene in patients or controls
was normalized with the baseline intensity and resulted in the fold change of relative intensity. The interferon score was a sum of relative intensity for
the nine genes (shown in Fig. 5b) that were significantly enriched in the interferon pathway. d Hierarchical clustering of the differentially methylated
CpG sites on the upregulated genes associated with the interferon signaling pathway. Hypomethylated CpG sites were identified in all the upregulated
IFN genes. e The CpG sites in MX1, IFIT1 and IFIT3 genes were hypomethylated in SLE patients comparing with NC. *Indicates p < 0.05. f The mRNA
expression of IFN genes (IFT1, IFT3 and MX1) were reversely correlated with the methylation status of the CpG sites in PBMC. NC normal controls, SLE
systemic lupus erythematosus, SLE LN+ SLE with lupus nephritis, SLE LN− SLE without lupus nephritis
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Fig. 5 Upregulated genes in PBMC of SLE were significantly enriched in the toll-like receptor signaling pathway. a A diagram showing the toll-like
receptor signaling pathway and upregulated genes involved in the network. b Array-based mRNA expression represented by normalized intensity in
SLE LN+, SLE LN−, and normal controls.*Indicates p < 0.05 as compared to normal controls. c The CpG sites in EIF2AK2 and IRAK3 genes were
hypomethylated in SLE patients compared with NC. *Indicates p < 0.05. NC normal controls, SLE systemic lupus erythematosus, SLE LN+ SLE
with lupus nephritis, SLE LN− SLE without lupus nephritis
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Fig. 6 Upregulated genes in PBMC of SLE LN+ patients. Three genes were identified to be significantly upregulated in SLE LN+ compared with
SLE LN− and NC (p < 0.05). Expression value represented by normalized intensity in SLE LN+, SLE LN−, and NC.*Indicates p < 0.05. NC normal
controls, SLE systemic lupus erythematosus, SLE LN+ SLE with lupus nephritis, SLE LN− SLE without lupus nephritis
a
b c
Fig. 7 Quantification of 27 cytokines and chemokines in sera of SLE patients and controls using bead-based multiplex assays. a Seventeen cytokines
showed significant difference in SLE patients compared with NC, 15 were increased and two were decreased in both SLE LN− and SLE LN+ compared
with NC (*p < 0.05). b mRNA expression level in PBMC for the cytokines which showed significant difference in sera of SLE patients. IL-15 mRNA was
significantly upregulated and CCL5 mRNA were downregulated in PBMC of SLE patients compared with NC (*p < 0.05). c Six CpG sites in the IL-15 gene
were hypomethylated and three CpG sites in CCL5 (RANTES) gene were hypomethylated in PBMC of SLE compared with NC. (*p < 0.05). NC normal
controls, SLE systemic lupus erythematosus, SLE LN+ SLE with lupus nephritis, SLE LN− SLE without lupus nephritis
Zhu et al. Arthritis Research & Therapy  (2016) 18:162 Page 12 of 17
with matched normal controls. By cross comparison of
different SLE groups with NC, we identified a group of
genes (552 up- and 550 downregulated) which are consist-
ently differentially expressed in SLE as compared with
controls. DNA methylation analysis on the whole-genome
level distinguished a large number of CpG sites which
were differentially methylated (1813 hypermethylated and
3785 hypomethylated sites) in SLE compared to NC. With
integrated analysis of the gene transcription and DNA
methylation data, we found that 60.5 % of the upregulated
genes contain hypomethylated CpG sites and 87.1 %
downregulated genes harbor hypermethylated CpG sites
in their regulatory regions of the genome, suggesting that
DNA methylation may have regulatory effect on most of
the differentially expressed genes in SLE. Profiling mRNA
expression and DNA methylation in the same set of SLE
and NC samples enable us to investigate the complexity of
gene dysregulation in the context of this disease.
Further analysis was performed to elucidate the potential
molecular pathways modulated by the aberrantly expressed
and methylated genes in SLE. The current analysis was
mainly focused on the common upregulated genes with
DNA hypomethylation. To our expectation, the upregu-
lated genes in SLE were significantly enriched in immune
regulatory pathways such as IFN signaling pathway, TLR
signaling pathway, and proinflammatory signaling path-
ways, which have been reported to be related with patho-
genesis in SLE and other autoimmune disorders [32–34]. It
is well known that the overexpression of type I IFN-related
genes in peripheral blood immune cells is a major SLE sig-
nature [35]. However, the pathogenic role of IFNs and their
exact regulation in the development of SLE is still under
debate. By exploring the globe gene transcription and
DNA methylation in PBMC of SLE with different clinical
manifestations (with or without LN), our study provided
further evidence that the overexpression of a cluster of IFN
genes was involved in the activation of the IFN signaling
pathway. In addition, we noticed a stepwise increased
expression of nine IFN genes from NC to SLE LN− to SLE
LN+, suggesting a pathogenic role of the IFNs in the devel-
opment of SLE and LN, even though the difference
between SLE LN− and SLE LN+ was not statistically signifi-
cant for all IFNs except for MX1. Interestingly, almost all
the overexpressed IFN genes in SLE were associated with
multiple hypomethylated CpG sites in the regulatory re-
gion of the genes, indicating epigenetic modification may
play a major role in the regulation of IFN gene expression.
Previous studies have reported the hypomethylation of IFN
genes in the CD4+ T cells in SLE [13]. Our study detected
the hypomethylated CpG sites in association with upregu-
lation of IFN genes in PBMC of SLE, suggesting the hypo-
methylation may be a general regulating mechanism in all
immune cells in PBMC, including T, B, macrophages, and
dendritic cells. Further studies need to be performed on
different cell types and different stages of the diseases to
elucidate the exact molecular mechanisms of IFN gene
regulation.
Toll-like receptor pathway is another molecular pathway
identified in our study to be enriched with dysregulated
genes in SLE. Seven upregulated genes in both SLE LN−
and SLE LN+, including TLR1, TLR4, TLR7, TLR8, CD14,
EIF2AK2 and IRAK3, were involved in the regulation of
TLR pathways. TLR regulation plays an essential role in
the pathogenesis of SLE [36]. It is believed that abnormal
activation of TLR7/TLR8 or TLR9 by self RNA or DNA in
antigen-presenting cells may cause breach of immune
tolerance and results in cytokine, IFN-I, and autoantibody
production in T, B, and myeloid cells [37–39]. TLR4 have
also been shown to induce TNF-α production in mono-
cytes of SLE patients [40, 41]. Substantial studies have
been focused on the TLR signaling pathway for explor-
ation of therapeutic target using adjuvants or inhibitors
[42, 43]. Our data revealed the aberrant DNA methyla-
tion of TLR and its signaling pathway in SLE, implying
a novel therapeutic strategy by intervention of methyla-
tion in SLE.
Serum cytokines/chemokines are important biomarkers
reflecting immune cell activation and inflammatory reac-
tion during the development of SLE [44]. In this study, we
measured the serum levels of 27 pre-inflammatory cyto-
kines/chemokines in SLE patients with or without lupus
nephritis and compared them with healthy controls. Our
analysis identified 15 cytokines/chemokines which signifi-
cantly increased in the sera of both SLE LN− and SLE LN+
patients, as compared with NC. The increased levels of Th1
cytokines (IL-2, IL-12, IL-15, TNF-a), and Th2 cytokines
(IL-4, IL-5, IL-6, IL-10,) reflecting the activation of both
Th1 and Th2 T helper cell subsets, which is in agreement
with previous studies showing that IL-12, IL-10, IL-6 and
TNF-α were correlated with active SLE [45–48]. We also
observed the increased level of IL-17, which is secreted by
Th17 cells and involved in T cell activation and autoanti-
bodies in SLE [49–51]. It is not surprising that we could
not find significant difference on any of the serum cyto-
kines between SLE LN+ and SLE LN− in our sample set. Al-
though several cytokines, including MCP-1, IP-10 and IL-6,
have been reported to have increased expression in the kid-
ney and urine of SLE patients with active LN compared
with no renal SLE, the serum level were not different be-
tween SLE patients with or without LN [52], implying that
the serum levels of inflammatory cytokines/chemokines
are not reflecting the LN activity in SLE patients.
Our data also showed that RANTES (CCL5) and
platelet-derived growth factor-BB (PDGF-BB) were signifi-
cantly lower in both SLE LN− and SLE LN+ compared
with NC. RANTES, as a proinflammatory chemokine, has
been extensively studied and reported to be increased in
SLE patients [53, 54]. The discrepancy of our data with
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previous studies may be due to sample variation and
different method used. PDGF-BB is a platelet-derived
factor involved in cell proliferation. Its role in SLE has not
been reported before.
The regulation of the serum cytokines/chemokines in
SLE on the genome level was not fully understood. By ana-
lyzing the mRNA expression and the DNA methylation of
the cytokine/chemokine genes, we were able to find out if
the increased serum level of cytokines in SLE is associated
with their mRNA transcription and DNA methylation in
the PBMC of the patients. To our surprise, we only found
two out of the 17 differentially expressed cytokines, the IL-
15 and RANTES, in which the mRNA expression in PBMC
correspond with their serum levels. The discrepancy
between serum protein level and mRNA for most of the
cytokines/chemokines may be due to the cytokine gene ex-
pression regulation is cell-type specific and the differential
expression may not be detected in PBMC, which is a mix-
ture of different cell types. On the other hand, the increased
mRNA transcription on IL-15 in SLE PBMC suggesting the
transcription of this cytokine may be activated in multiple
cell types. Indeed, IL-15 can be produced by macrophage/
monocytes, activated NK cells, CD4+ T cells, and B cells,
and involved in the pathogenesis of SLE and other auto-
immune diseases [55–57]. Furthermore, the hypomethyla-
tion on several CpG sites in the regulatory region of this
gene suggested a strong epigenetic regulation of IL-15 in
SLE. In addition, our study showed that the lower level of
RANTES in serum is correlated with lower mRNA expres-
sion in PBMC in SLE patients. Interestingly, the hyper-
methylated CpG sites at the 5′UTR region of CCL5
(RANTES) gene in SLE patients also indicated a suppres-
sive effect of epigenetic regulation on this gene. This data is
currently under validation in a larger sample cohort.
LN is one of the most devastating complications of
SLE, but the molecular basis for this disease is not yet
clear. Gene expression profiling on PBMC and different
subsets of blood cells have identified candidate genes
that might contribute to the pathogenesis of SLE and its
complications [7, 58, 59]. However, the role of the differ-
entially expressed genes identified from peripheral blood
of SLE patients in the pathogenesis of LN is still under
debate. By comparing the gene expression profiles in
PBMC from SLE LN− and SLE LN+ patients, we identi-
fied three genes which are significantly elevated in SLE
LN+ patients, namely, MX1, GPR84 and E2F2. MX1 is
one of the IFN-I-inducible genes which have been exten-
sively studied in SLE. Increased MX1 gene expression
has been detected in both PBMC and renal intrinsic cells
of lupus nephritis patients suggesting its role in the
pathogenesis of LN [60, 61]. Our data consolidated
previous finding by detecting the upregulation of MX1
on transcription in PBMC and in serum in SLE LN+ pa-
tients. Furthermore, by analyzing DNA methylation of
this gene, we postulated that the higher expression of
MX1 in SLE may be regulated by hypomethylation of
the CpGs in the regulatory region.
E2F2 and GPR84 are novel biomarkers which have not
been previously reported to be associated with SLE or LN.
E2F2 is a member of E2F transcription factor family. As a
cell cycle activator, E2F2 can regulate the gene expression
that govern the cell cycle and DNA synthesis, and thus
cell proliferation [62, 63]. There was a study that showed
that E2F2 can promote the expression of microRNA let-7a
by binding to its promoter and let-7a has been shown to
contribute to hyperplasia and the proinflammatory re-
sponse in SLE [64]. Therefore, the increased expression of
E2F2 may associate with the inflammation in SLE and LN.
GPR84 is a G protein-coupled receptor for sensing free
fatty acid and active inflammatory reaction. Activation of
GPR84 by its ligand could elicit chemotaxis of poly-
morphonuclear leukocytes (PMNs) and macrophages and
amplified lipopolysaccharide (LPS)-stimulated production
of the proinflammatory cytokine IL-8 from PMNs and
TNF-α from macrophages [65]. Further analysis on the
expression of these two genes in different cell types and
the molecular pathways is warranted to elucidate their
role in the pathogenesis of SLE and LN.
Although our current analysis was primarily focused on
the genes which were upregulated and hypomethylated in
SLE, the identification of a large amount of downregulated
genes which were hypermethylated in the SLE genome by
globe gene expression and DNA methylation analysis im-
plying that downregulation or silencing of gene expression
in PBMC may play an equally important role in SLE and
LN [66–70]. Previous studies have demonstrated that the
downregulation of IL-2 [35, 67, 71], IL-17 [66], and
Notch-1 [69] in SLE T lymphocytes was due to the bind-
ing cAMP-responsive element modulator (CREM)-α to
the promoter of the genes followed by enhanced CpG
DNA methylation. We therefore examined methylation
status on the CpG sites of these genes in our study. By
comparing the mean β value between NC and SLE (both
with LN and without LN involvement), we found that four
out of 70 sites on Notch-1 gene, two out of ten sites on
IL-17A gene and one out of two sites on IL-2 gene were
hypermethylated in SLE (p < 0.05) (data not shown).
Further analysis on the SLE downregulation gene data set
is going on with the expectation to find out more dysregu-
lated pathways modulated by DNA hypermethylation.
There are some limitations in the current study. First,
the gene expression and DNA methylation profiling were
only performed in PBMC. Given the highly complex na-
ture of this disease, different cell subsets in peripheral
blood may have different transcription and methylation
profiles during the development of the diseases. However,
previous studies using different cell types have identified
specific gene signatures from different cell types. These
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cell type-specific genes allowed a correct classification of
PBMC independent from their heterogenic cellular com-
position. Therefore, based on the expression of cell type-
specific signature genes, we should be able to normalize
the expression profile of PBMC from all individuals [72].
On the other hand, the advantage of using PBMC includes
easy accessibility and less blood volume requirement. The
result from PBMC has reflected a general picture of profil-
ing alteration in whole blood. It is therefore ideal for
biomarker screening [73]. The second limitation is that
the sample size in this study is relatively small. The statis-
tical power may not be strong enough to draw conclusions
on some of the differential genes and pathways. The
current data will need to be further validated in a larger
sample cohort. Third, functional analysis will need to be
conducted to confirm the genetic and epigenetic interac-
tions on the dysregulation of genes and pathways in SLE.
Conclusions
In conclusion, we integrated the gene expression, DNA
methylation, and cytokine profiling data in PBMC of SLE
patients with and without lupus nephritis. Our study has
demonstrated that significant number of differential genes
in SLE were involved in IFN, TLR signaling pathways, and
inflammatory cytokines. The enrichment of differential
genes has been associated with aberrant DNA methyla-
tion, which may be relevant to the pathogenesis of SLE.
Our observations have laid the groundwork for further
diagnostic and mechanistic studies of SLE and LN.
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